Accession Number: | 0001562180-20-001123 |
Date: | 2020-02-10 |
Issuer: | CONSTELLATION PHARMACEUTICALS INC (CNST) |
Original Submission Date: |
REEVE EMMA
C/O CONSTELLATION PHARMACEUTICALS, INC.
215 FIRST STREET, SUITE 200
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-10 | M | 200 | a | $7.60 | 200 | direct | ||
COMMON STOCK | 2020-02-10 | S | 200 | d | $35.00 | 0 | direct | ||
COMMON STOCK | 2020-02-11 | M | 7,212 | a | $7.60 | 7,212 | direct | ||
COMMON STOCK | 2020-02-11 | S | 7,212 | d | $35.04 | 0 | direct | ||
COMMON STOCK | 2020-02-11 | M | 1,430 | a | $8.04 | 1,430 | direct | ||
COMMON STOCK | 2020-02-11 | S | 1,430 | d | $35.04 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 7.6 | 2020-02-10 | deemed execution date | M | 200 (d) | 2028-03-05 | common stock 200 | $7.60 | 28,412 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 8.04 | 2020-02-11 | deemed execution date | M | 1,430 (d) | 2028-04-22 | common stock 1,430 | $8.04 | 36,266 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 7.6 | 2020-02-11 | deemed execution date | M | 7,212 (d) | 2028-03-05 | common stock 7,212 | $7.60 | 21,200 | direct |
ID | footnote |
---|---|
f1 | this transaction was executed in multiple trades at prices ranging from $35.00 to $35.095. the price reported above reflects the weighted average price. the reporting person hereby undertakes to provide upon request to the sec staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
f2 | this option was granted on march 6, 2018. the shares underlying the option are scheduled to vest in equal quarterly installments through december 6, 2021. |
f3 | this option was granted on april 23, 2018. the shares underlying the option are scheduled to vest in equal quarterly installments through october 23, 2021. |